- -- 29 September 2009
- immatics appoints Carsten Reinhardt as Chief Medical Officer
- -- 10 August 2009
- immatics obtains further important EP patents covering its lead product IMA901 and US patent for MUC-1 peptide
- -- 17 June 2009
- immatics biotechnologies significantly improves XPRESIDENT™ technology platform
- -- 02 March 2009
- immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer
- -- 26 January 2009
- immatics wins 29th German Industry's Innovation Award (Innovationspreis der deutschen Wirtschaft)
- -- 23 January 2009
- Dr. Jürgen Frisch (Chief Medical Officer) to leave immatics
Dr. Jürgen Frisch (Chief Medical Officer) to leave immatics
Tuebingen, January 23, 2009 – After four years of successfully leading clinical development at immatics, including moving forward two of immatics’ product candidates from pre-clinical stage into phase II studies, Dr. Frisch has decided to follow new career opportunities. He will leave immatics at the end of January 2009.
We would like to thank him for the significant contribution he has made to the clinical development and regulatory progress made by immatics and to wish him well with his future career.
immatics Management Team